Point72 Asset Management, L.P. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:02 pm Sale |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Point72 Asset Management, L.P. | 115,484 0.200% |
-1,644,764 (-93.44%) |
Filing |
| 2022-02-14 4:26 pm Purchase |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Point72 Asset Management, L.P. | 1,760,248 5.000% |
8,685 (+0.50%) |
Filing |
| 2021-12-13 4:58 pm Purchase |
2021-12-10 | 13G | Akero Therapeutics, Inc. AKRO |
Point72 Asset Management, L.P. | 1,751,563 5.000% |
1,751,563 (New Position) |
Filing |